Janssen-Cilag Ltd are the UK marketing authorisation holder.
Invokana® tablets (canagliflozin hemihydrate)
Patient Information LeafletVokanamet® (canagliflozin/metformin)
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.
Patient Information LeafletIf you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this medicine.
Adverse events concerning Invokana and Vokanamet should also be reported to Janssen-Cilag Limited on
01494 567447 or dsafety@its.jnj.com.
We own and maintain the following websites:
Information for patients receiving Invokana
You are now leaving s://napp.co.uk. Napp does not accept any responsibility for the third party site.
Please click "Continue to external link" if you want to proceed.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Settings. More Info.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!
More information about our Cookie Policy